866-997-4948(US-Canada Toll Free)

Systemic Lupus Erythematosus - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Nov 2010

Category :

Therapeutic Area

No. of Pages : 50 Pages


GlobalData, the industry analysis specialists new report, Systemic Lupus Erythematosus Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global systemic lupus erythematosus market. The report identifies the key trends shaping and driving the global systemic lupus erythematosus market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global systemic lupus erythematosus sector. 

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalDatas team of industry experts

GlobalData estimated the Systemic Lupus Erythematosus (SLE) market to be worth $350 million in 2009 with a projected Compound Annual Growth Rate (CAGR) of 6% and projected market value to exceed $2.5 billion in 2017. Products for systemic lupus erythematosus in developmental pipeline are strong. The pipeline molecules have a distinct advantage over the currently used off-label marketed drugs. These molecules are primarily first-in-class molecules displaying the robustness of the systemic lupus erythematosus pipeline. 

GlobalData finds that the launch of pipeline products may have a superior efficacy in overcoming with the currently marketed products. However, several compounds are in development, and it must be hoped that, many will bring significant relief to number of systemic lupus erythematosus patients in reducing the symptoms. With all these market constraints, the only rational outcome for the new launches would be to provide more safety profile and better efficacy, cost advantage to the market in systemic lupus erythematosus market. 

Scope

The scope of the report includes: 

  • Annualized global systemic lupus erythematosus market revenues data from 2001 to 2009, forecast forward for 8 years to 2017. 
  • Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan. 
  • Pipeline analysis data providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include T and B cell modulators, Immunomodulators, Hormonal Agents, phosphodiesterase type 4inhibitor, Anti Alpha INF, Interleukin inhibitors and anti CD antigens. 
  • Analysis of the current and future market competition in the global systemic lupus erythematosus market. Key market players covered are F. Hoffmann-La Roche Ltd (Genentech) , MedImmune, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, UCB S.A, Amgen and Biogen Idec. 
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with systemic lupus erythematosus.
Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global systemic lupus erythematosus market. 
  • Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global systemic lupus erythematosus market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • Whats the next big thing in the global systemic lupus erythematosus market landscape? Identify, understand and capitalize.
Table Of Content

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET : INTRODUCTION

2.1 GlobalData Pipeline Report Guidance

3 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET : MARKET CHARACTERIZATION

3.1 Overview
3.2 Systemic Lupus Erythematosus Market Size
3.3 Systemic Lupus Erythematosus Market Forecast and CAGR
3.4 Drivers and Barriers for the Systemic Lupus Erythematosus Market
3.4.1 Drivers for the Systemic Lupus Erythematosus Market
3.4.2 Barriers for the Systemic Lupus Erythematosus Market
3.5 Opportunity and Unmet Need
3.6 Key Takeaway

4 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET : COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Therapies and Off-Label Marketed Products in the SLE Market
4.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4.3.2 Corticosteroids
4.3.3 Immunosuppressant or Cytotoxic Drugs
4.4 Key Takeaway

5 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET : PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 SLE Therapeutics – Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
5.4.1 Benlysta (belimumab)
5.4.2 Atacicept
5.4.3 Ocrelizumab (Humanized Anti-CD20 monoclonal antibody)
5.4.4 Prestara™
5.4.5 Epratuzumab
5.4.6 Lupuzor
5.5 Systemic Lupus Erythematosus Therapeutics – Pipeline by Clinical Phases of Development
5.5.1 Systemic Lupus Erythematosus Therapeutics – Phase III Clinical Pipeline
5.5.2 Systemic Lupus Erythematosus Therapeutics – Phase II Clinical Pipeline
5.5.3 Systemic Lupus Erythematosus Therapeutics – Phase I Clinical Pipeline
5.5.4 Systemic Lupus Erythematosus Therapeutics – Preclinical Pipeline
5.5.5 Systemic Lupus Erythematosus Therapeutics – Discovery Pipeline
5.6 Discontinued/Suspended Drugs for Systemic Lupus Erythematosus
5.7 Key Takeaway

6 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET : IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET: FUTURE PLAYERS

7.1 Introduction
7.2 Biogen Idec
7.2.1 Overview
7.2.2 Autoimmune Portfolio
7.3 MedImmune
7.3.1 Overview
7.3.2 Autoimmune Portfolio
7.4 F. Hoffmann-La Roche (Genentech)
7.4.1 Overview
7.4.2 Autoimmune Portfolio
7.5 Amgen Inc
7.5.1 Overview
7.5.2 Autoimmune Portfolio
7.6 Bristol-Myers Squibb
7.6.1 Overview
7.6.2 Autoimmune Portfolio
7.7 UCB S.A
7.7.1 Overview
7.7.2 Autoimmune Portfolio
7.8 GlaxoSmithKline plc
7.8.1 Overview
7.8.2 Autoimmune Portfolio

8 SYSTEMIC LUPUS ERYTHEMATOSUS MARKET : APPENDIX

8.1 Market Definitions
8.2 Scope of Pipeline Research
8.3 Abbreviations
8.4 Research Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Forecasting
8.4.4 Primary Research
8.4.5 Expert Panel validation
8.5 Contact Us
8.6 Disclaimer
8.7 Sources 50

List of Table


Table 1: SLE Therapeutics, Global, Revenue ($m), 20012009 8
Table 2: Global SLE Therapeutics, Revenue ($m), 200920017 8
Table 3: SLE Therapeutics Most Promising Drugs Under Clinical Development, 2010 19
Table 4: Systemic Lupus Erythematosus Therapeutics Phase III Clinical Pipeline, 2010 26
Table 5: Systemic Lupus Erythematosus Therapeutics Phase II Clinical Pipeline, 2010 27
Table 6: Systemic Lupus Erythematosus Therapeutics Phase I Clinical Pipeline, 2010 28
Table 7: Systemic Lupus Erythematosus Therapeutics Preclinical Pipeline, 2010 29
Table 8: Systemic Lupus Erythematosus Therapeutics Discovery Pipeline, 2010 29
Table 9: List of Discontinued/Suspended Drugs for Systemic Lupus Erythematosus, 2010 29
Table 10: Biogen Idec Autoimmune Marketed Products, 2010 33
Table 11: Biogen Idec Autoimmune Pipeline Products, 2010 33
Table 12: MedImmune Autoimmune Pipeline Products, 2010 34
Table 13: F. Hoffmann-La Roche Ltd Autoimmune Marketed Products, 2010 35
Table 14: F. Hoffmann-La Roche Ltd Autoimmune Pipeline Products, 2010 35
Table 15: Amgen Inc Autoimmune Marketed Products, 2010 36
Table 16: Amgen Inc Autoimmune Pipeline Products, 2010 37
Table 17: Bristol-Myers Squibb Autoimmune Marketed Products, 2010 37
Table 18: Bristol-Myers Squibb Autoimmune Pipeline Products, 2010 38
Table 19: UCB S.A Autoimmune Marketed Products, 2010 38
Table 20: UCB S.A Autoimmune Pipeline Products, 2009 39
Table 21: GlaxoSmithKline plc Autoimmune Marketed Products, 2010 40
Table 22: GlaxoSmithKline plc Autoimmune Pipeline Products, 2010 40

List of Chart


Figure 1: SLE Therapeutics, Global, Revenue ($m), 20012009 7
Figure 2: SLE Therapeutics, Global, Market Forecast ($m), 20092017 8
Figure 3: Opportunity and Unmet Need in SLE Therapeutics Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Off-Label Products for SLE, 2010 13
Figure 5: Technology Trends Analytic Framework of the SLE Pipeline, 2010 18
Figure 6: Technology Trends Analytic Framework of the SLE Pipeline - Description, 2010 18
Figure 7: Systemic Lupus Erythematosus Pipeline by Phases of Clinical Development, 2010 26
Figure 8: Implications for Future Market Competition in the SLE Market, 2010 31
Figure 9: Systemic Lupus Erythematosus Market Clinical Pipeline by Company, 2010 32
Figure 10: GlobalData Market Forecasting Model 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *